Riverview Trust Company’s Axcelis ACLS Stock Holding History

Riverview Trust Company’s Portfolio ACLS Stock Details ACLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-255	Closed	-$14K	–	711
2022 Q2	$14K	Buy	+255	New	+$14.8K	0.01%	503

Other funds holding ACLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Riverview Trust Company's ACLS Position: Q3 2022 in Review

Riverview Trust Company sold out of Axcelis (ACLS) in Q3 2022, closing a stake of 255 shares — an estimated $14K sold.

Riverview Trust Company first reported a position in ACLS in Q2 2022 and held it in 1 quarter. The position peaked at $14K in Q2 2022. 287 funds tracked by Wall St. Rank hold ACLS as of Q3 2022.

Riverview Trust Company reported no remaining Axcelis position as of Q3 2022 after selling out during the quarter.
Riverview Trust Company sold 255 Axcelis shares in Q3 2022, an estimated $14K.
Riverview Trust Company first reported a position in Axcelis in Q2 2022 and held it in 1 quarter.
Riverview Trust Company's Axcelis position peaked at $14K in Q2 2022.
287 funds tracked by Wall St. Rank held Axcelis as of Q3 2022.

Based on Riverview Trust Company's 13F filing for Q3 2022, filed 27 Oct 2022.